INTRODUCTION

Cardiac CSQ
1 is concentrated in junctional sarcoplasmic reticulum (SR) terminal cisternae as part of the multimeric Ca 2+ -release channel complex (1) (2) (3) (4) (5) (6) (7) (8) that includes the cardiac O 'Brian et al., page 3 ryanodine receptor (9, 10) , junctin (11) , and cardiac triadin-1 (12) . The cardiac isoform of CSQ (13, 14) exhibits 65% sequence identity to the fast-twitch form (15) , but its carboxyl terminus extends an additional 24 residues and contains CK2 phosphorylation sites (16) . Cardiac SR has been morphologically and biochemically characterized as consisting of two major compartments, known as free SR, and junctional SR which forms terminal cisternae apposing tubular invaginations of the sarcolemma (1, (17) (18) (19) . How the components of the Ca 2+ -release channel complex are targeted to this one locale is not known, but early studies suggested that biogenesis of junctional SR and free SR involve different pathways (20) (21) (22) . Furthermore, cellular transport of cardiac CSQ is thought to be different form the fast-twitch protein (13) , which is thought to transit through the Golgi complex (4) to terminal cisternae.
Both CSQ isoforms are substrates for protein kinase CK2 in vitro (16, 23) , and phosphorylation sites have been determined for canine cardiac and rabbit fast-twitch isoforms (16) . The fast-twitch isoform is phosphorylated on 373 Thr, while the cardiac isoform is phosphorylated on a cluster of three serine residues that reside in the cardiac-specific tail ( 378,382,386
Ser). These three serine residues were previously shown to be partially phosphorylated in the purified cardiac isoform, whereas no phosphate appeared in the rabbit fast-twitch isoform (16) . A function for CSQ phosphorylation by CK2 has not been determined, however a mechanism for sorting of resident ER and Golgi proteins by CK2 phosphorylation on cytosolic sites has been characterized (24) (25) (26) (27) (28) (29) (30) .
In this report, we report definitive structural findings for CSQ revealed by mass spectrometry that reflect its cellular transport in heart and muscle cells. CSQ glycosylation and phosphorylation, while highly similar in nonmuscle cells as diverse as human HEK and insect resuspended at 1 mg/ml in buffer A containing 20 mM MOPS, pH 7.5, 250 mM NaCl, 1 % CHAPS, 0.5 mM EGTA, and 0.5% of a protease inhibitor cocktail (Sigma). Included in the buffer was 10 mM NaF and 10 mM β-glycerophosphate to inhibit protein phosphatases.
Extracts were centrifuged at 50,000 x g x 20 min, bound to DEAE-Sephacel (Pharmacia), then washed extensively in buffer B (buffer A without CHAPS) until detergent was removed. CSQ was eluted in buffer B with 750 mM NaCl. Eluate was loaded onto phenyl agarose and purification carried out as previously described (35) with calsequestrin eluted in purified form by adding 20 mM CaCl 2 to the elution buffer. SDS-PAGE was carried out according to Laemmli (36) . Protein assays were carried out using a Lowry protocol (37) .
Purification of native CSQ from canine cardiac and skeletal muscle tissue -Native CSQs from canine left ventricles and hind leg muscles were also purified as previously described (35) New Haven CT using a Q-ToF mass spectrometer (Micromass, Altrincham, UK). Prior to analysis samples were desalted using C-4 ZipTips (Millipore, Corp., Bedford, MA). The eluted samples in 50% acetonitrile/0.1% formic acid were analyzed using the nanospray technique in positive ion mode. Masses were calculated using the Q-Tof's MassLynx software. Spectra were calibrated using either sodium iodide or the fragment ions from the MS/MS spectrum of (Glu)fibrinogen (Sigma).
RESULTS
Cardiac CSQ purified from dog heart contains significant levels of phosphate (>1 mol/mol) on a carboxy-terminal cluster of serine residues that are in vitro substrates of protein kinase CK2. To determine whether this reaction is unique to heart cells, we analyzed the purified CSQ from HEK and Sf21 cells, following heterologous expression in nonmuscle cells using a recombinant adenovirus or baculovirus. CSQ purification from canine skeletal muscle led to isolation of both CSQ isoforms, with the fast-twitch form (63 kDa) being the predominant one, as previously reported (38) .
Application of our phosphatase/CK2 kinase assay to the skeletal muscle preparation showed that, as in heart tissue, cardiac CSQ (55 kDa) was present mainly as the phosphoprotein (Fig.   1B ), whereas the canine fast-twitch isoform did not accumulate in a phosphorylated form ( To try and resolve individual forms of phosphorylated CSQ, we subjected purified CSQ to mass spectrometry using electrospray ionization. Mass spectrometry of purified wild-type CSQ from HEK cells showed a series of mass peaks differing by about 81 Da, consistent with a mixture of molecules differing by a single phosphate moiety ( Mass spectrometry of native CSQ purified from canine ventricular tissue gave a mass spectrum that was more complex than that from HEK and Sf21 cells (Fig. 3, upper Again, glycoforms and phosphoforms are schematically shown in Fig. 4 . The mass peak at 46,398 Da represents Man3 plus 2 phosphates, but may also contain molecules of Man4 with no phosphate, in which case it appears that these molecules are also not phosphorylated in vivo as there is no peak corresponding to Man4 plus 3 phosphates. In summary, Man1,3 are partially to fully phosphorylated in vivo, whereas Man4-6 remain unphosphorylated.
To compare the mass spectrum for the fast-twitch isoform, we purified CSQ from canine hind leg muscle by a procedure identical to that for heart tissue. The mass spectrum for the skeletal muscle protein (Fig. 3 , lower panel) consisted of only two protein peaks, separated by 323 Da, a difference of two mannose residues, a pattern which appears to be maintained in the notable in the fast-twitch isoform was the absence of phosphate in the two observed glycoforms, a finding in agreement with our in vitro phosphorylation data (Fig. 1B) .
In Fig. 4 , we have summarized the data from the mass spectra, providing a schematic view of the distributions of CSQ glyco-and phosphoforms. In cases where mass peaks probably contain contributions from more than one glycoform, we have approximated relative contributions, as detailed in the figure legend. 
DISCUSSION
Phosphorylation of CSQ is an active process in all cells
Cardiac CSQ contained between 1.5 and 2.0 mol P i /mol protein on CK2 sites, whether biosynthesized in canine heart or in non-muscle cells. Phosphorylation of cardiac CSQ varied from nonphosphorylated to fully (3 mol/mol) phosphorylated. Interestingly, nonmuscle cells contained sufficient calsequestrin kinase to produce high steady levels of the phosphorylated protein, even upon overexpression to levels comparable to that of heart cells. Mass spectrometry showed similar patterns of phosphorylation on similar glycoforms in human and insect cells, indicating an extraordinary conservation of protein processing, and suggesting that phosphorylation of lumenal ER/SR proteins may be a ubiquitous cellular reaction. Although the mechanism and precise cellular compartmentation remains uncertain, it appears that CSQ phosphorylation involves CK2 or a CK2-like protein kinase which co-localizes with CSQ, if only transiently.
CSQ Glycan Processing in ER and SR
In all cells, CSQ glycosylation occurred on only one of its two potential N-glycosylation sites -likely 316 Asn since this site is highly conserved among species and isoforms (40) . myotubes. A mechanism whereby CSQ could move through the Golgi complex in muscle but is unable to move beyond the ER in nonmuscle represents an interesting area for future research.
Cell biology of phosphorylated cardiac CSQ
Cardiac CSQ exhibited a complex pattern of phosphorylation on molecules that are clearly processed within the secretory pathway, whereas the fast-twitch isoform was not phosphorylated, consistent with results of point mutants using this isoform (49, 50) . Cardiac CSQ existed in a broad range of glycoforms; those which contained phosphate (Man1,3) and those lacking phosphate (Man4-6). The pattern of phosphorylated glycoforms suggest that transit to specific compartments may require prior phosphorylation, or that some compartments may contain a CSQ phosphatase. It is also possible that phosphorylated glycoforms of cardiac CSQ do not co-localize with non-phosphorylated glycoforms, a possibility that is under current In some cases, contributions from more than one isoform are predicted to comprise a single peak in the mass spectrum and individual components are approximated as follows: a, mass peak 46,398 Da in heart CSQ ( Fig. 3, upper panel) was assumed to contain Man3 (plus 2 phosphates) and Man4 glycoforms (indicated by connecting bar ) in a 2 to 1 ratio; b, mass peak 47,135 Da in HEK CSQ (Fig. 2, panel A) was assumed to contain equal amounts of two isoforms as shown, and c, mass peak 47,295 Da (same spectrum) was assumed to contain Man9 and Man8 glycoforms in a 2 to 1 ratio.
Individual glycoform contributions from overlapping mass peaks for Sf21 CSQ were approximated the same as for HEK CSQ.
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